PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
IPO Year: 2013
Exchange: NASDAQ
Website: ptcbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $80.00 | Buy | Truist |
| 5/9/2025 | $68.00 | Neutral → Buy | BofA Securities |
| 5/7/2025 | $40.00 | Sell → Neutral | Citigroup |
| 3/11/2025 | $41.00 → $55.00 | Underperform → Neutral | BofA Securities |
| 3/7/2025 | $55.00 | Sector Perform | Scotiabank |
| 12/13/2024 | $45.00 → $67.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/3/2024 | $39.00 → $63.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 10/10/2024 | Mkt Perform | Raymond James | |
| 9/4/2024 | $44.00 | Outperform | Robert W. Baird |
| 8/26/2024 | $47.00 | Buy | UBS |
Truist initiated coverage of PTC Therapeutics with a rating of Buy and set a new price target of $80.00
BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00
Citigroup upgraded PTC Therapeutics from Sell to Neutral and set a new price target of $40.00
BofA Securities upgraded PTC Therapeutics from Underperform to Neutral and set a new price target of $55.00 from $41.00 previously
Scotiabank initiated coverage of PTC Therapeutics with a rating of Sector Perform and set a new price target of $55.00
Morgan Stanley upgraded PTC Therapeutics from Equal-Weight to Overweight and set a new price target of $67.00 from $45.00 previously
RBC Capital Mkts upgraded PTC Therapeutics from Sector Perform to Outperform and set a new price target of $63.00 from $39.00 previously
Raymond James resumed coverage of PTC Therapeutics with a rating of Mkt Perform
Robert W. Baird initiated coverage of PTC Therapeutics with a rating of Outperform and set a new price target of $44.00
UBS resumed coverage of PTC Therapeutics with a rating of Buy and set a new price target of $47.00